数据链接：
官方服务：
资源简介：
Incidence rate of adverse drug events (ADRs).
应用场景：
创建时间：
2014-03-10
相关数据集
ATN 061 Chemistry Results Electrolytes and Creatinine Dataset in Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/ritonavir (ATV/r) in Adolescents and Young Adults with CD4 + T Cells > 350 cells/mm3 Initiating HAART
Data from Chemistry Results Form [CRF 11, serum electrolytes and creatinine testing results table] Study Description A randomized, proof-of-concept study of adolescents and young adults aged 18-24 yea
NIAID Data Ecosystem70
A comprehensive exploration of adverse reactions to lapatinib: a disproportionate analysis based on the FAERS database
Lapatinib, an FDA-approved tyrosine kinase inhibitor, treats HER2+ advanced/metastatic breast cancer. This study comprehensively analyzed its adverse reaction profile using FDA Adverse Event Reporting
Taylor & Francis Group2025-12-05 更新50
Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database
Fostamatinib, an FDA-approved oral small-molecule spleen tyrosine kinase (SYK) inhibitor, is used to treat thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have not responded
DataCite Commons2026-04-23 更新60
Post-marketing safety of panitumumab: a real-world pharmacovigilance study
Panitumumab has been extensively applied in antitumor therapy, and the regulation of its adverse drug reactions (ADRs) has become extremely important. This study utilized the U.S. Food and Drug Admini
NIAID Data Ecosystem50
